SG11201407194XA - Trehalose-containing mammalian cell suspension for prevention of pulmonary embolism formation - Google Patents

Trehalose-containing mammalian cell suspension for prevention of pulmonary embolism formation

Info

Publication number
SG11201407194XA
SG11201407194XA SG11201407194XA SG11201407194XA SG11201407194XA SG 11201407194X A SG11201407194X A SG 11201407194XA SG 11201407194X A SG11201407194X A SG 11201407194XA SG 11201407194X A SG11201407194X A SG 11201407194XA SG 11201407194X A SG11201407194X A SG 11201407194XA
Authority
SG
Singapore
Prior art keywords
mammalian
cells
stem cells
trehalose
formation
Prior art date
Application number
SG11201407194XA
Other languages
English (en)
Inventor
Tamaki Wada
Masako Doi
Takeshi Kikuchi
Eiji Kobayashi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG11201407194XA publication Critical patent/SG11201407194XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11201407194XA 2012-05-08 2013-05-02 Trehalose-containing mammalian cell suspension for prevention of pulmonary embolism formation SG11201407194XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012106866A JP5432322B2 (ja) 2012-05-08 2012-05-08 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
PCT/JP2013/002925 WO2013168403A1 (ja) 2012-05-08 2013-05-02 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液

Publications (1)

Publication Number Publication Date
SG11201407194XA true SG11201407194XA (en) 2014-12-30

Family

ID=49550467

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407194XA SG11201407194XA (en) 2012-05-08 2013-05-02 Trehalose-containing mammalian cell suspension for prevention of pulmonary embolism formation

Country Status (13)

Country Link
US (1) US10265346B2 (ja)
EP (1) EP2848683B1 (ja)
JP (1) JP5432322B2 (ja)
KR (1) KR20150013154A (ja)
CN (1) CN104271735B (ja)
AU (1) AU2013259255B2 (ja)
CA (1) CA2872460C (ja)
ES (1) ES2614881T3 (ja)
HK (1) HK1205756A1 (ja)
NZ (1) NZ701665A (ja)
SG (1) SG11201407194XA (ja)
TW (1) TWI577379B (ja)
WO (1) WO2013168403A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493023B2 (en) 2013-05-07 2019-12-03 Seelos Therapeutics, Inc. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
BR112017006533A2 (pt) * 2014-09-29 2017-12-19 Cook General Biotechnology Llc usos de trealose em suspensões celulares
WO2018123628A1 (ja) * 2016-12-28 2018-07-05 ロート製薬株式会社 細胞医薬組成物、疾患治療用キット及び細胞懸濁用溶液
TW202315937A (zh) 2021-09-08 2023-04-16 日商蓋亞生物製藥有限公司 細胞之處理方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3253131B2 (ja) 1992-07-24 2002-02-04 洋巳 和田 移植臓器用溶液
EP0762897B1 (en) * 1994-06-02 2003-04-02 Elan Drug Delivery Limited Method of preventing aggregation of proteins/peptides upon rehydration or thawing
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
JPH114682A (ja) * 1997-06-16 1999-01-12 Asahi Medical Co Ltd 有核細胞保存方法、有核細胞保存用組成物及び有核細胞分離方法
FR2787464B1 (fr) 1998-12-21 2003-01-10 Neurotech Compositions pharmaceutiques comprenant des cellules endotheliales immortalisees pour la detection et/ou le traitement des sources angiogeniques et tout particulierement des cancers
US6280718B1 (en) 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
CN100557023C (zh) 2001-06-08 2009-11-04 株式会社载体研究所 利用vsv-g假型化猴免疫缺陷病毒载体将基因导入灵长类胚胎干细胞
JP5274017B2 (ja) 2005-10-13 2013-08-28 株式会社大塚製薬工場 肝臓保存液
CN101374941A (zh) * 2005-12-29 2009-02-25 人类起源公司 采集和保存胎盘干细胞的改良组合物及其使用方法
JP2009296889A (ja) * 2008-06-10 2009-12-24 Foundation For Biomedical Research & Innovation 造血幹細胞の培養方法
KR20200011604A (ko) * 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
US20110208162A1 (en) * 2008-10-24 2011-08-25 Indiana University Rsearch and Technology Corporation Methods for preventing aggregation of adipose stromal cells
JP6027300B2 (ja) * 2009-03-19 2016-11-16 国立大学法人岩手大学 細胞または臓器の保存液および保存方法
JP2010251273A (ja) 2009-04-16 2010-11-04 Norio Sudo 多重管構造蛍光管
JP5341059B2 (ja) 2010-11-09 2013-11-13 株式会社大塚製薬工場 幹細胞懸濁液

Also Published As

Publication number Publication date
US20150118196A1 (en) 2015-04-30
ES2614881T3 (es) 2017-06-02
CN104271735A (zh) 2015-01-07
JP2013233102A (ja) 2013-11-21
AU2013259255B2 (en) 2018-04-05
CN104271735B (zh) 2017-08-04
EP2848683A1 (en) 2015-03-18
EP2848683B1 (en) 2016-12-21
NZ701665A (en) 2016-09-30
EP2848683A4 (en) 2015-10-21
WO2013168403A1 (ja) 2013-11-14
TWI577379B (zh) 2017-04-11
CA2872460A1 (en) 2013-11-14
JP5432322B2 (ja) 2014-03-05
AU2013259255A1 (en) 2014-11-27
CA2872460C (en) 2018-06-05
US10265346B2 (en) 2019-04-23
HK1205756A1 (en) 2015-12-24
TW201402136A (zh) 2014-01-16
KR20150013154A (ko) 2015-02-04

Similar Documents

Publication Publication Date Title
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201407194XA (en) Trehalose-containing mammalian cell suspension for prevention of pulmonary embolism formation
SG11201804934PA (en) Novel Compounds
SG11201407837WA (en) Beta-hairpin peptidomimetics
SG11201809132RA (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201810605UA (en) Selectively altering microbiota for immune modulation
SG11201811221XA (en) Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof
AU2014386720B2 (en) Uric acid-lowering agent
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201809752VA (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201407961WA (en) Risperidone or paliperidone implant formulation
SG11201805052YA (en) Therapeutic methods using erythrocytes
SG11201803642WA (en) Bacteria-based protein delivery
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201803949RA (en) Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
SG11201807540UA (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
SG11201804965SA (en) Augmented acid alpha-glucosidase for the treatment of pompe disease
SG11201909856XA (en) Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11201909334TA (en) Proteins for the treatment of epithelial barrier function disorders
SG11201807963WA (en) Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus
SG11201805755SA (en) Methods of administering hepcidin